PubMed Health⌕ Search

Biomedical subjects

E F Pfeiffer

Publications and source records attributed to E F Pfeiffer.

At least 217 records · Page 12Linked to original sources
PubMed1978

Studies on the pituitary "Fettstoffwechselhormon". VIII. Radioimmunoassay of the lipolytic factor P-LF II D.

A radioimmunoassay of the lipolytic peptide P-LF II D from porcine pituitaries is described. The assay is performed with 125-iodine labeled P-LF II D and with antisera either from guinea pigs or from rabbits. Bound antigen is separated from the free by double antibody technique. No cross reaction is observed with gamma lipotropin, peptide B, secretin, glucagon, isoproterenol. Due to contamination P-LF II C, beta lipotropin and human growth hormone displace the tracer when added at large doses. Complete cross reaction is observed between porcine 1-39 ACTH and P-LF II D. Specificity of this reaction is demonstrated by the increase of cross reaction, when ACTH fragments of increasing length of the polypeptide chain are used (1-23 ACTH, 1-24 ACTH and 1-28 ACTH).

Adrenocorticotropic Hormone↗
PubMed1978

The effect of high maltose and sucrose feeding on glucose tolerance.

This study records an impaired glucose tolerance in rats fed a high sucrose or maltose containing diet as compared to an isocaloric starch rich food. At low sugar concentrations only the 50% sucrose containing diet produced a significantly elevated blood glucose following an oral glucose load, whereas 20% sucrose feeding exhibited no differences as compared to long-term starch feeding. While body weights and basal blood sugar levels were similar in all diet groups, the glucose-induced insulin release was significantly higher in rats with a glucose tolerance of a diabetic type. In these animals serum triglycerides were also markedly elevated. The present results indicate, that the metabolic response to the ingestion of carbohydrates depends on the type of carbohydrate in previous nutrition. In view of a known genetic susceptibility regarding sucrose, similar conditions are suggestive for maltose.

Animals↗
PubMed1978

C-peptide secretion during the remission phase of juvenile diabetes.

C-peptide secretion was studied in eight juvenile diabetics during the remission phase of the disease. The release of C-peptide was measured after a (1) normal intravenous glucose tolerance test, (2) a double glucose tolerance test, (3) an arginine infusion, and (4) after an intravenous glucose tolerance test followed by an arginine infusion. Under all conditions the intravenous glucose load had only a minimal effect on the secretion of C-peptide, while arginine alone or after the intravenous glucose tolerance test stimulated the release of the peptide in all patients. Pretreatment with glucose did not augment the effect of arginine on C-peptide release. The results indicate that during the remission phase of juvenile-onset diabetes the endocrine pancreas does not recognize glucose as and appropriate signal for C-peptide release and cannot transform the amplifying effect of glucose into a higher hormonal secretion rate.

Adolescent↗
PubMed1977

Paradoxical ACTH response to glucocorticoids in Cushing's disease.

To define further the defect in the steroid feedback mechanism in Cushing's disease, we studied the acute effects of intravenous administration of glucorticoids on plasma ACTH levels in seven patients with this disease after total adrenalectomy. In seven other patients with hypoadrenocorticism ACTH was readily suppressed; a significant decrease (72.5+/-5 per cent, mean +/- S.E.M., P less than 0.002) occurred within 15 minutes of the start of an infusion of 50 mg per hour of cortisol. In contrast, in the seven adrenalectomized patients with Cushing's disease, cortisol induced a transient paradoxical rise in ACTH levels, with a maximum at 15 minutes (347+/-99 per cent,, P less than 0.05). A similar ACTH response was observed with dexamethasone. Cushing's disease is characterized by a paradoxical transient rise in ACTH after glucocorticoid administration. This effect was more pronounced in adrenalectomized than in nonadrenalectomized patients.

Adolescent↗
PubMed1977

[Insulin treatment of decompensated diabetes mellitus with a new artificial endocrine pancreas (author's transl)].

During the past decades insulin has been given in relatively high doses when treating diabetic coma. Recently low-dose insulin treatment has been proposed by several groups. In the reported investigation insulin was initially given in moderate to high doses (12-200 U/h) with a steady reduction in dose during the course of treatment. Insulin infusion was regulated either manually with an adjustable infusion pump (7 patients) or automatically with an artificial endocrine pancreas (glucose-controlled insulin infusion system; 11 patients). Thus 18 patients with decompensated diabetes mellitus (coma or precoma) were treated. In 14 patients with ketoacidotic decompensation laboratory data on hospital admission were: blood glucose 7.35 +/- 0.61 g/l, serum potassium 4.7 +/- 0.4 mmol/l, pH 7.1 +/- 0.04, base excess - 19,7 +/- 2.2 mmol/l (x +/- SEM). The other patients had hyperglycaemic or hyperosmolar non-ketotic decompensation. In all patients controlled reduction of blood glucose levels was achieved within 2.3 to 18 hours. The amounts of insulin infused during this ranged from 17 to 320 units, but in one instance was 1950 units. There were no complications.

Adolescent↗
PubMed1977

Estimation of cholecystokinin-pancreozymin (CCK) in human plasma and tissue by a specific radioimmunoassay and the immunohistochemical identification of pancreozymin-producing cells in the duodenum of humans.

A reliable, sensitive, reproducible and specific radioimmunoassay for cholecystokinin-pancreozymin (CCK) has been developed, using rabbit antisera to highly purified porcine hormone. The natural occurring variant of CCK (39-CCK), in which the ordinary CCK is lengthened from its N-terminus by a hexapeptide, labelled with 125J, and repurified by column chromatography on Sephadex G-10 and on SP-Sephadex C-25, was used as tracer. Separation from antibody-bound labelled 39-CCK was carried out using a double antibody procedure. Non-specific interference with the assay system was abolished by ethanol extractions. Highly purified porcine CCK was used as standard. No significant crossreaction was found with gastrin, motilin, vasoactive polypeptide (VIP), gastric inhibitory polypeptide (GIP), natural and synthetic secretin, pancreatic glucagon or insulin. The sensitivity of the assay is approximately 40 pg/ml of test solution. The mean immunoreactive CCK concentration in 45 fasting normal subjects was 222 pg/ml increasing after food ingestion to 480 pg/ml. Somatostatin was able to abolish the stimulated CCK release. Elevated CCK concentrations were found in chronic pancreatitis. Immunohistochemical identification of pancreozymin cells was carried out either in surgical samples or in biopsy material. Approximately 1650 CCK cells per cross-section in the duodenum of humans have been found. The CCK cells usually appeared elongated, oval or pyramidal in shape and were observed to reach the lumen with their apical cell pole.

Animals↗
PubMed1977

Inhibition of cholecystokinin-pancreozymin release by somatostatin.

To determine the effect of somatostatin on cholecystokinin-pancreozymin (C.C.K.) release, serum-C.C.K. concentrations were measured in normal volunteers after intraduodenal olive oil, with and without a simultaneous intravenous infusion of somatostatin. After instillation of the olive oil there was a rapid rise in serum-C.C.K. (integrated response 19 682+/-5632 pg min ml-1). This rise was completely abolished by somatostatin (integrated response -373+/-330 pg min ml-1, P less than 0-005) and rebound hyper-secretion was seen after the infusion had been stopped. These findings indicate that somatostatin may be involved in regulating C.C.K. release after meals, and suggest a possible explanation for the profound steatorrhoea seen in a patient with a somatostatin-producing tumour.

Adult↗